Streetbeat News

Price Targets

AVDL

Piper Sandler analyst David Amsellem has maintained an Overweight rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and raised the price target from $13 to $18.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:32 pm

ARHS

Piper Sandler analyst Peter Keith maintains an Overweight rating on Arhaus (NASDAQ:ARHS) and raises the price target from $13 to $16.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:30 pm

GCMG

Piper Sandler analyst Sumeet Mody maintains an Overweight rating on GCM Grosvenor (NASDAQ:GCMG) and raises the price target from $9 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:29 pm

HUM

Unusual options activity has been observed for Humana (NYSE:HUM), with a significant bullish stance taken by a large investor. The sentiment among these big-money traders is split 50% bullish and 50% bearish. The targeted price range for Humana over the last 3 months is from $440.0 to $500.0. Several financial institutions have maintained their ratings on Humana, with price targets ranging from $541 to $637.

Portfolio Pulse from Benzinga Insights

August 10, 2023 | 7:16 pm

ATMU

Atmus Filtration Techs (NYSE:ATMU) has received 7 bullish and somewhat bullish analyst ratings in the last quarter, with no bearish or indifferent ratings. The average 12-month price target for the stock, according to 7 analysts, is $26.57, up 2.19% from the previous average of $26.00.

Portfolio Pulse from Benzinga Insights

August 10, 2023 | 6:00 pm

RELI

EF Hutton analyst Michael Albanese has reiterated a 'Buy' rating on Reliance Global Group (NASDAQ:RELI) and maintained a price target of $7.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 5:52 pm

IKNA

HC Wainwright & Co. analyst Andres Maldonado has reiterated a 'Buy' rating on Ikena Oncology (NASDAQ:IKNA) and maintained a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 5:51 pm

TTD

Susquehanna analyst Shyam Patil maintains a positive outlook on Trade Desk (NASDAQ:TTD) and raises the price target from $90 to $105.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 5:51 pm

CBAY

HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on CymaBay Therapeutics (NASDAQ:CBAY), maintaining a price target of $19.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 5:50 pm

SMCI

Susquehanna analyst Mehdi Hosseini maintains a Neutral rating on Super Micro Computer (NASDAQ:SMCI) and raises the price target from $90 to $300.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 5:50 pm